Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women

References

• Anonymous. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183:S1--22
   Google Scholar
• ACOG. ACOG practice bulletin (No. 33) – diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002, reaffirmed 2010;99:159–67
   Google Scholar
• Turner JA. Diagnosis and management of pre-eclampsia: an update. Int J Women’s Health 2010;2:327–37
   PubMedGoogle Scholar
• Saftlas AF, Olason DR, Franks AL, et al. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol 1990;163:460–65
   PubMed Web of Science ®Google Scholar
• Duckitt K, Harrington D. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. Br Med J 2005;330:565
   PubMed Web of Science ®Google Scholar
• Eskenazi B, Fenster L, Sidney S. A multivariate analysis of risk factors for preeclampsia. J Am Med Assoc 1991;266:237–41
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Investig 2003;111:649–58
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young investigator award. Am J Obstet Gynecol 2004;190:1541–50
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642–9
   PubMed Web of Science ®Google Scholar
• Moore Simas TA, Crawford SL, Solitro MJ, et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007;197:244.e1--8
   Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. New Engl J Med 2004;350:672–83
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C. Soluble endoglin and other circuliating antiangiogenic factors in preeclampsia. New Engl J Med 2006;355:992–1005
   PubMed Web of Science ®Google Scholar
• Rana S, Karumanchi SA, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007;50:137–72
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Johnson DD. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol 2007;197:174e1–5
   Google Scholar
• Maynard SE, Moore Simas TA, Bur L, et al. Soluble endoglin for the prediction of preeclampsia in a high risk cohort. Hypertens Pregn 2010;29:330–41
   PubMed Web of Science ®Google Scholar
• Maynard SE, Moore Simas TA, Solitro MJ, et al. Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. Am J Obstet Gynecol 2008;198:200.e1--7
   Web of Science ®Google Scholar
• ACOG. ACOG Practice Bulletin (No. 101): ultrasonography in pregnancy. Obstet Gynecol 2009;113:451--61
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560--72
   PubMed Web of Science ®Google Scholar
• Cleveland WS. Visualizing data. Summit, NJ: Hobart Press; 1993
   Google Scholar
• Bassett GW, Koenker R. An empirical quantile function for linear models with iid errors. J Am Stat Assoc 1982;77:401–15
   Google Scholar
• Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. New York: Wiley; 2004
   Google Scholar
• Qin G, Hotilovac L. Comparison of non-parametric confidence intervals for the area under the ROC curve of a continuous-scale diagnostic test. Stat Methods Med Res 2008;17:207–21
   PubMed Web of Science ®Google Scholar
• Le CT. A solution for the most basic optimization problem associated with an ROC curve. Stat Methods Med Res 2006;15:571–84
   PubMed Web of Science ®Google Scholar
• Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021–38
   PubMed Web of Science ®Google Scholar
• Polliotti BM, Fry AG, Saller DN, et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003;101:1266–74
   PubMed Web of Science ®Google Scholar
• Sibai BM, Koch MA, Freire S, et al. Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol 2008;199:268 e1–9
   Web of Science ®Google Scholar
• Levine RJ, Qian C, Maynard SE, et al. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstetr Gynecol 2006;194:1034–41
   PubMed Web of Science ®Google Scholar
• Myatt L, Clifton RG, Roberts JM, et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstetr Gynecol 2012;119:1234–42
   PubMed Web of Science ®Google Scholar
• Rohra DK, Zeb A, Qureishi RN, et al. Prediction of pre-eclampsia during early pregnancy in primiparas with soluble fms-like tyrosine kinase-1 and placental growth factor. Natl Med J India 2012;25:68–73
   PubMedGoogle Scholar
• Vatten LJ, Eskild A, Nilsen TI, et al. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007;196:239 e1–6
   PubMed Web of Science ®Google Scholar
• Poon LC, Akolekar R, Lachmann R, et al. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11–13 weeks. Ultrasound Obstet Gynecol 2010;35:662–70
   PubMed Web of Science ®Google Scholar
• Espinoza J, Romero R, Nien JK, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007;196:326 e1–13
   PubMed Web of Science ®Google Scholar
• Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007;49:818–24
   PubMed Web of Science ®Google Scholar
• Crispi F, Llurba E, Dominguez C, et al. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008;31:303–9
   PubMed Web of Science ®Google Scholar
• Mijal RS, Holzman CB, Rana S, et al. Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. J Matern Fetal Neonatal Med 2012;25:1135–41
   PubMed Web of Science ®Google Scholar
• Straughen JK, Kumar P, Misra VK. The effect of maternal soluble FMS-like tyrosine kinase 1 during pregnancy on risk of preterm delivery. J Matern Fetal Neonatal Med 2012;25:1879–83
   PubMed Web of Science ®Google Scholar
• Romero R, Chaiworapongsa T, Erez O, et al. An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. J Matern Fetal Neonatal Med 2010;23:1384–99
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9–23
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Espinoza J, Gotsch F, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008;21:25–40
   PubMed Web of Science ®Google Scholar
• Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008;21:279–87
   PubMed Web of Science ®Google Scholar
• Espinoza J, Romero R, Nien JK, et al. A role of the anti-angiogenic factor sVEGFR-1 in the ‘mirror syndrome' (Ballantyne's syndrome). J Matern Fetal Neonatal Med 2006;19:607–13
   PubMed Web of Science ®Google Scholar
• Kusanovic JP, Romero R, Espinoza J, et al. Twin-to-twin transfusion syndrome: an antiangiogenic state? Am J Obstet Gynecol 2008;198:382 e1–8
   PubMed Web of Science ®Google Scholar
• Su YN, Lee CN, Cheng WF, et al. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol 2001;97:898–904
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Savasan ZA, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011;24:1187–207
   PubMed Web of Science ®Google Scholar
• Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. Br J Obstet Gynaecol 2012;119:778–87
   Google Scholar
• Sibai BM, Koch MA, Freire S, et al. Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol 2008;199:268. e1–268.e9
   PubMed Web of Science ®Google Scholar
• Powers RW, Jeyabalan A, Clifton RG, et al. Soluble fms-like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PlOS One 2010;5:e13263. 1–12
   PubMed Web of Science ®Google Scholar
• Dwyer BK, Krieg S, Balise R, et al. Variable expression of soluble fms-like tyrosine kinase 1 in patients at high risk for preeclampsia. J Matern Fetal Neonatal Med 2010;23:705–11
   PubMed Web of Science ®Google Scholar
• Verlohren S, Herraiz I, Lapaiare O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders an dits prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012;206:58. e1–8
   PubMedGoogle Scholar
• Villa PM, Kajantie E, Raikkonen K, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG 2013;120:64–74
   PubMed Web of Science ®Google Scholar
• Group THSCR. Hyperglycemia and adverse pregnancy outcomes. New Engl J Med 2008;258:1991–2002
   Google Scholar
• Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble Fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011;124:940–50
   PubMed Web of Science ®Google Scholar
• Perni U, Sison C, Sharma V, et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012;59:740–6
   PubMed Web of Science ®Google Scholar